Pirbuterol
- Atc Codes:R03AC08#R03CC07
- CAS Codes:65652-44-0#38677-81-5
- PHARMGKB ID:65652-44-0#38677-81-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Maxair, Pirbuterol; Luxembourg: Spirolair.
North America
USA: Maxair.
Drug combinations
Chemistry
Pirbuterol Acetate: C~12~H~20~N~2~O~3~ C~2~H~4~O~2~. Mw: 300.35. (1) 2,6-Pyridinedimethanol, α^6^-[[(1,1-dimethylethyl)amino]methyl]-3-hydroxy-, monoacetate; (2) α^6^-[(tert-Butylamino)methyl]-3-hydroxy-2,6-pyridinedimethanol monoacetate. CAS-65652-44-0; CAS-38677-81-5 (pirbuterol)(1978).
Pharmacologic Category
Bronchodilators; Selective β~2~-Adrenergic Agonists. (ATC-Code: R03AC08; R03CC07).
Mechanism of action
A β~2~-adrenergic agonist with similar structure to albuterol. The increased β~2~-selectivity of pirbuterol results from substitution of tertiary butyl group on nitrogen of side chain, which additionally imparts resistance of pirbuterol to degradation by monoamine oxidase and provides lengthened duration of action in comparison to less selective previous β-agonist agents.
Therapeutic use
Prevention and treatment of reversible bronchospasm including asthma.
Pregnancy and lactiation implications
Use caution during pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to pirbuterol, albuterol, or any component of the formulation.
Warnings and precautions
Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents. Recommended dose should not be exceeded (risk of serious adverse events). Should not be used as component of chronic therapy without anti-inflammatory agent. β-agonists may cause elevation in blood pressure, heart rate, and result in CNS stimulation/excitation (use with caution in cardiovascular disease). β~2~-Agonists may also increase risk of arrhythmias. Use with caution in diabetes mellitus (β~2~-agonists may increase serum glucose), glaucoma (may elevate intraocular pressure), hyperthyroidism (may stimulate thyroid activity), hypokalemia (β~2~-agonists may decrease serum potassium), and in seizure disorders (β-agonists may result in CNS stimulation/excitation).